Cardiovascular effects of recombinant human erythropoietin in predialysis patients

American Journal of Kidney Diseases

Volumn 29, Issue 4, 1997, Pages 541-548

  Portolés, Jose ^a   Torralbo, Antonio ^b   Martin, Piedad ^b   Rodrigo, Jose ^b   Herrero, Jose A ^b   Barrientos, Alberto ^b  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

^b NONE

Author keywords

Chronic renal failure; erythropoietin; hemodynamics; left ventricular hypertrophy

Indexed keywords

ADRENALIN; DOPAMINE; ENDOTHELIN; NORADRENALIN; RECOMBINANT ERYTHROPOIETIN; RENIN;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR EFFECT; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART OUTPUT; HEMODYNAMICS; HUMAN; MALE; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030903823     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-6386(97)90335-8     Document Type: Article

References (28)

1. Teehan BP, for the US Recombinant human erythropoietin Predialysis Study Group: Double-blind, placebo-controlled study of the therapeutic use of rHuEPO for anemia associated with chronic renal failure in predialysis patients. Am J Kidney Dis 18:50-59, 1991
2. Garcia DL, Anderson S, Renke HG, Brenner BM: Anemia lessens and its prevention with rHuEPO worsens glomerular injury and hypertension in rats with reduced renal mass. Proc Natl Acad Sci U S A 85:6142-6146, 1988
3. Torralbo A, Blanco J, Fontanellas A, Herrero JA, Cruceira A, Gonzalez-Lopez P, Barrientos A: Long-term EPO in rats with reduced renal mass. Nephron 73:280-285, 1996
4. London GM, Zins B, Pannier B, Naret C, Berthelot JM, Jaquot C, Safar M, Drueke TB: Vascular changes in hemodialysis patients in response to rHuEPO. Kidney Int 36:878-882, 1989
5. Adamson JW, Eschbach JW: Treatment of the anemia of chronic renal failure with rHuEPO. Ann Rev Med 41:349-360, 1990
6. Harnett JD, Perfrey PS: Left ventricular disfunction in dialysis patients, in Henrich WL (ed): Principles and Practice of Dialysis. Baltimore, MD, Williams & Wilkins, 1995, pp 170-180
7. Low I, Grutzmacher P, Bergmann M, Schoeppe W: Echocardiographic findings in patients on maintenance hemodialysis patients substituted with rHuEPO. Clin Nephrol 31:26-30, 1989
8. Harnett JD, Parfrey PS, Griffiths SM, Gault MH, Barre T, Guttmann RD: Left ventricular hypertrophy in end stage renal disease. Nephron 48:107-115, 1987
9. Pascual J, Teruel JL, Mota JL, Liafio F, Jimenez-Mena M, Ortuño J: Regression of left ventricular hypertrophy after partial correction of anemia with rHuEPO in patients on hemodialysis. A prospective study. Clin Nephrol 35:280-287, 1991
10. Silberberg JS, Rahal DP, Patton R, Snidermann AD: Role of anemia in the pathogenesis of LVH in ESRD. Am J Cardiol 64:222-224, 1989
11. Degoulet P, Legrain M, Reach I, Aime F, De Vries P, Rojas P, Jacobs C: Mortality risk factors in patients treated in chronic hemodialysis. Nephron 31:103-110, 1982
12. Silberberg JS, Barre PE, Prichard SS, Sniderman AD: Impact of LVH on survival in ESRD. Kidney Int 36:286-290, 1989
13. Fellner SK, Lang RM, Neumann A, Korcarz C, Borrow K: Cardiovascular consequences of correction of the anemia of the renal failure with rHuEPO. Kidney Int 44:1309-1315, 1993
14. Koch KM, Koene RAP, Messinger D, Quarder O, Scigalla P: The use ofepoietin beta in predialysis patients with chronic renal failure. Clin Nephrol 44:201-208, 1995
15. Austrian Multicenter Study Group of rHuEPO in Predialysis: Effectiveness and safety of rHuEPO in predialysis patients. Nephron 61:399-403, 1992
16. Van de Borne P, Tielmans JG, Vanherweghem L, Degaute JP: Effect of rHuEPO therapy on ambulatory blood pressure and heart rate in chronic bemodialysis patients. Nephrol Dial Transplant 7:45-49, 1992
17. Shan DJ, De Mora A, Kisslo J, Weyman A: Recommendations regarding quantitation in M-mode echocardiography: Result of a survey of ECHO measurement. Circulation 58:1072-1083, 1978
18. Lewis JF, Kuo LC, Nelson JC, Limacher MC, Quiñones MA: Pulsed doppler echocardiographic determination of stroke volume and cardiac output: Clinical validations of two new methods using apical windows. Circulation 70:425-431, 1984
19. Devereux RB, Koren MJ, Simone G, Okin PM, Kligfield P: Methods of detection of LVH: Application to hypertensive heart disease. Eur Heart J 14:D8-D15, 1993 (suppl D)
20. Kamahori M, Taki M, Watanabe Y, Miura J: Analysis of plasma catecholamines by HPLC with fluorescence detection. J Chromatogr 567:351-358, 1991
21. Satoh K, Masuda T, Ikeda J, Kurokawa S, Kikiwada R, Takamoto T, Maruno F: Hemodynamic changes by EPO therapy in hemodialyzed patients. Hypertension 15:262-266, 1990
22. Carlini R, Obialo CI, Rothstein M: Intravenous rHuEPO administration increases plasma endothelin and blood pressure in hemodialysis. Am J Hypertens 6:103-107, 1993
23. Martin J, Moncada S: Blood pressure rHuEPO and nitric oxide. Lancet 2:644, 1988
24. Torralbo A, Herrero JA, Portoles J, Fontanellas A, Barrientos A: Activation of the sympathetic nervous system in hemodialyzed patients treated with EPO. Nephron 69:350, 1995
25. Natsume T: Therapeutic advances in the treatment of LVH. Eur Heart J 14:D33-D37, 1993
26. London GM, Marchais SJ, Guerin AP, Metivier F, Bruno P: Cardiac hypertrophy and arterial alterations in ESRD: Hemodynamic factors. Kidney Int 43:S42-S49, 1993 (suppl 41)
27. Levy D, Anderson KM, Savage DD, Kannel WB, Christiansen JC, Castelli WP: Echocardiographically detected left ventricular hypertrophy: Prevalence and risk factors: The Framingham Heart Study. Ann Intern Med 108:7-13, 1988
28. Wizeman V, Schäfer R, Kramer W: Follow-up of cardiac changes induced by anemia compensation in normotensive HD patients with LVH. Nephron 64:202-206, 1993